-
DOJ Case Against Live Nation Is 'Weak,' Analysts Say: 'Separating Ticketmaster... Is Unlikely To Lower Ticket Prices'
Friday, May 24, 2024 - 1:14pm | 550Read More...The Department of Justice filed an antitrust lawsuit against Live Nation Entertainment (NYSE:LYV), which sent shares down during the week. Analysts react to the news and share what's ahead for the entertainment company. The LYV Analysts: Guggenheim analyst Curry Baker has a Buy rating and $128...
-
Analysts Praise Target's Q3 Results, Gross Margins, But Have Cautious Tone For Future: Retailer 'Facing The Largest Macro Headwinds'
Thursday, November 16, 2023 - 2:11pm | 859Read More...Retailer Target Corp (NYSE:TGT) reported third-quarter financial results that included revenue and earnings per share coming in ahead of estimates from analysts. Here's a look at what analysts are saying about the company after the report. The Target Analysts: Bank of America analyst Robert F....
-
Analysts Weigh In On Amended Bluebird Bio/Celgene Deal
Thursday, June 4, 2015 - 11:53am | 355Read More...Bluebird bio Inc (NASDAQ: BLUE) and Celgene Corporation (NASDAQ: CELG) announced a restructuring of its CAR-T collaboration this week. Under the amended terms of the deal, the collaboration will focus on CAR-T cells that target the B-cell maturation antigen (BCMA). Celgene will also provide $25...
-
Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth
Tuesday, October 7, 2014 - 4:19pm | 264Read More...Sunesis Pharmaceuticals, Inc.'s (NASDAQ: SNSS) failed cancer drug vosaroxin offers no reason for investors to give up hope on other companies' potential cures, an analyst said Tuesday. Sunesis said Tuesday its vosaroxin drug for acute myeloid leukemia failed to show effectiveness in a...
